| Name | Title | Contact Details |
|---|
Newport Healthcare is changing the face of behavioral health services for teens, young adults and their families by providing sustainable healing.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
On Demand Pharmaceuticals (ODP) is developing the worlds most sophisticated distributed manufacturing platform.
Analytical Bio-Chemistry (ABC) Laboratories, Inc. is a GLP and CGMP-compliant contract laboratory with expertise in analytical services and radiolabeling synthesis. From its inception in 1968, ABC Laboratories has been dedicated to solving scientific